Maughan T - Search Results

1

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.

Karapetis CS, Liu H, Sorich MJ, Pederson LD, Van Cutsem E, Maughan T, Douillard JY, O'Callaghan CJ, Jonker D, Bokemeyer C, Sobrero A, Cremolini C, Chibaudel B, Zalcberg J, Adams R, Buyse M, Peeters M, Yoshino T, de Gramont A, Shi Q. Karapetis CS, et al. Among authors: maughan t. Br J Cancer. 2024 May;130(8):1269-1278. doi: 10.1038/s41416-024-02604-y. Epub 2024 Feb 24. Br J Cancer. 2024. PMID: 38402342 Free PMC article. Clinical Trial.

2

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.

Hanna CL, McKinna FE, Williams LB, Morrey D, Adams M, Mason MD, Maughan TS. Hanna CL, et al. Among authors: maughan ts. Br J Cancer. 1995 Sep;72(3):774-6. doi: 10.1038/bjc.1995.409. Br J Cancer. 1995. PMID: 7669593 Free PMC article. Clinical Trial.

3

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.

Melcher AA, Mort D, Maughan TS. Melcher AA, et al. Among authors: maughan ts. Br J Cancer. 1996 Nov;74(10):1651-4. doi: 10.1038/bjc.1996.604. Br J Cancer. 1996. PMID: 8932350 Free PMC article. Clinical Trial.

4

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, Vincent M, Schulz J, González Barón M, Facchini T. Cunningham D, et al. Among authors: maughan ts. Eur J Cancer. 2002 Mar;38(4):478-86. doi: 10.1016/s0959-8049(01)00413-0. Eur J Cancer. 2002. PMID: 11872339 Review.

5

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP. Cassidy J, et al. Among authors: maughan ts. Br J Cancer. 2006 Apr 24;94(8):1122-9. doi: 10.1038/sj.bjc.6603059. Br J Cancer. 2006. PMID: 16622438 Free PMC article. Clinical Trial.

6

A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network.

Adams R, Morgan M, Mukherjee S, Brewster A, Maughan T, Morrey D, Havard T, Lewis W, Clark G, Roberts S, Vachtsevanos L, Leong J, Hardwick R, Carey D, Crosby T. Adams R, et al. Among authors: maughan t. Eur J Surg Oncol. 2007 Apr;33(3):307-13. doi: 10.1016/j.ejso.2006.10.026. Epub 2006 Nov 22. Eur J Surg Oncol. 2007. PMID: 17123775

7

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.

Adams R, Maughan T. Adams R, et al. Among authors: maughan t. Expert Rev Anticancer Ther. 2007 Apr;7(4):503-18. doi: 10.1586/14737140.7.4.503. Expert Rev Anticancer Ther. 2007. PMID: 17428171 Review.

8

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH. Folprecht G, et al. Among authors: maughan ts. J Clin Oncol. 2008 Mar 20;26(9):1443-51. doi: 10.1200/JCO.2007.14.0509. J Clin Oncol. 2008. PMID: 18349394

9

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.

Adams R, Meade A, Wasan H, Griffiths G, Maughan T. Adams R, et al. Among authors: maughan t. Expert Rev Anticancer Ther. 2008 Aug;8(8):1237-45. doi: 10.1586/14737140.8.8.1237. Expert Rev Anticancer Ther. 2008. PMID: 18699762 Review.

10

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.

Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, Kaplan RS, Maughan TS. Adams RA, et al. Among authors: maughan ts. Br J Cancer. 2009 Jan 27;100(2):251-8. doi: 10.1038/sj.bjc.6604877. Br J Cancer. 2009. PMID: 19165196 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

272 results

Search Page

Filters